Eiger BioPharmaceuticals, Inc. (EIGR) News
Filter EIGR News Items
EIGR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest EIGR News From Around the Web
Below are the latest news stories about EIGER BIOPHARMACEUTICALS INC that investors may wish to consider to help them evaluate EIGR as an investment opportunity.
Eiger BioPharmaceuticals Insiders US$2.1m Short Of Breakeven On Stock PurchaseInsiders who purchased US$3.42m worth of Eiger BioPharmaceuticals, Inc. ( NASDAQ:EIGR ) shares over the past year... |
Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdateEiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today reported financial results for the third quarter 2023 and provided a business update. |
Why Is Eiger BioPharmaceuticals (EIGR) Stock Down 31% Today?Eiger BioPharmaceuticals (EIGR) stock is falling on Wednesday after the biopharmaceutical company halted a Phase 3 clinical trial. |
Why Is Sigma Lithium (SGML) Stock Up 14% Today?Sigma Lithium (SGML) stock is climbing higher on Wednesday after confirming it has received multiple strategic proposals. |
WKHS Stock Alert: The $40,000 Reason Workhorse Is Up TodayWorkhorse (WKHS) stock is on the rise Wednesday thanks to a new update from the IRS concerning its electric vehicle (EV) manufacturer status. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayIt's time for another dive into the biggest pre-market stock movers as we check out all the shares worth watching on Wednesday! |
UPDATE 1-Eiger to discontinue hepatitis drug study over safety concernsEiger BioPharmaceuticals Inc said on Tuesday it would discontinue a late-stage study testing its experimental drug to treat the most severe form of viral hepatitis, due to safety concerns. The drug candidate, peginterferon lambda, was being tested in patients with chronic hepatitis delta (CHD). "The study discontinuation is disappointing, especially for patients with chronic hepatitis delta who have limited treatment options," said Eiger CEO David Apelian. |
Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis DeltaEiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced its decision to discontinue the Phase 3 LIMT-2 study of peginterferon lambda in patients with chronic hepatitis delta (CHD). The decision is based on the recommendation of the Data Safety Monitoring Board (DSMB) for the study following its quarterly safety review. In a communication dated September 7, 2023, the |
Eiger BioPharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment ConferenceEiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that David Apelian, MD, PhD, MBA, CEO of Eiger, will present a company overview at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023 at 7:00 AM ET in New York, NY. Eiger will also host one-on-one meetings with investors at the conference. |
While dollars continue to flow into biotech, companies cut more jobsBiotech continues to have a big impact on the local and state economy, a new report says. But mature clinical-stage companies also are struggling. |